Skip to content

Efficacy and safety of acclerated repetitive transcranial magnetic stimulation for patients with major depressive disorder

The efficacy and safety of accelerated repetitive transcranial magnetic stimulation (rTMS) compared with conventional rTMS in major depressive disorder: active treatment controlled, randomized, non-inferiority study

Status
Recruiting
Phases
Phase 4
Study type
Interventional
Source
CRIS
Registry ID
KCT0000666
Enrollment
30
Registered
2013-02-08
Start date
2012-08-23
Completion date
Unknown
Last updated
2019-03-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

Procedure/Surgery : Active treament group : accelerated rTMS (left prefrontal cortex, 10Hz, 110% of motor threshold), 5 sessions per day for 3 days Comparison group : conventional rTMS (left prefront

Sponsors

Yonsei University Health System, Gangnam Severance Hospital
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: - Patients taking two or less antidepressant medications without change of dosage within two weeks - Illness duation is less than 5 years - Montgomery-Asberg Depression Rating Scale score is equal to or higher than 22

Exclusion criteria

Exclusion criteria: - Patient who has other Axis I disoder including schizophrenia, bipolar disorder and so on. - Patient who has been treated with rTMS or electroconvulsive therapy. - Past history of seizure disorder - 1st degree family history of seizure disorder - Substance dependence or other medical illnesses which have significant effect on brain function - Organic brain disease such as brain tumor or intracranial hemorrhage - Patients who have taken medication lowering seizure threshold (ex: theophylline) - Patients who have artificial metal in the body (cochlear implantation or pacemaker) - Clinically inappropriate patient for rTMS

Design outcomes

Primary

MeasureTime frame
Hamilton Depression Rating Scale

Secondary

MeasureTime frame
Frequency, Intensity, Burden of Side Effect Rating scale

Countries

Korea, Republic of

Contacts

Public ContactJeong-Ho Seok

Yonsei University Health System, Gangnam Severance Hospital

Outcome results

None listed

Source: CRIS (via WHO ICTRP) · Data processed: Feb 4, 2026